Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe

• Published in: Applied health economics and health policy 2021-11, Vol.19 (6), p.915-927
• Main Authors: Vončina, Luka, Strbad, Tea, Fürst, Jurij, Dimitrova, Maria, Kamusheva, Maria, Vila, Megi, Mardare, Ileana, Hristova, Kristina, Harsanyi, Andras, Atanasijević, Dragana, Banović, Igor, Bobinac, Ana
• Format: Article
• Language: English
• Subjects: Capacity development; Cost-Benefit Analysis; Croatia; Decision making; Documents; Efficiency; Europe; Europe, Eastern; Funding; Health Administration; Health Economics; Humans; Hungary; Information dissemination; Languages; Legal documents; Literature reviews; Medicine; Medicine & Public Health; Money; Nonprescription Drugs; Original Research Article; Pharmaceutical industry; Pharmacoeconomics and Health Outcomes; Public finance; Public Health; Quality of Life Research; Reforms; Reimbursement; Rules; Stakeholders; Systematic review; Technology assessment; Transparency
• ISSN: 1175-5652; 1179-1896
• DOI: 10.1007/s40258-021-00678-w

Background Efficiency and transparency of pricing and reimbursement (P&R) rules and procedures as well as their implementation in South-eastern Europe (SEE) lag substantially behind Western European practice. Nevertheless, P&R systems in SEE are rarely critically assessed, warranting a detailed and wider-encompassing exploration. Objective Our study provides a comparative assessment of P&R processes for patent-protected medicines in ten SEE countries—EU member states: Croatia, Slovenia, Hungary, Romania and Bulgaria; and non-EU countries: Albania, Montenegro, Serbia, North Maceodina, Bosnia and Herzegovina. P&R systems are compared and evaluated through a research framework that focuses on: (1) public financing of patent-protected medicines, (2) definition of benefit packages, (3) requirements for the submission of reimbursement dossiers, (4) assessment and appraisal processes, (5) reimbursement decision making, (6) processes that occur post reimbursement, and (7) pricing. The study aims to contribute to the discussion on improving the efficiency and quality of P&R of patent-protected medicines in the region. Methods We conducted a non-systematic literature review of published literature, as well as policy briefs and reports on healthcare systems in the SEE region along with legal documents framing the P&R procedures in local languages. The information gathered from these various sources was then discussed and clarified through structured telephone interviews with relevant national experts from each SEE country, mainly current and former senior officials and/or executives of the funding and assessment/ appraisal bodies (total of 20 interviews conducted in late 2019). Results Capacity building through sharing knowledge and information on successful reforms across borders is an opportunity for SEE countries to further develop their P&R policies and increase (equitable) access to patent-protected medicines (especially expensive medicines), increasing affordability and containing costs. Simple yet robust and systematic decision-making frameworks that rely on international health technology assessment (HTA) procedures and are based on the pursuit of transparency seem to be the most cost-effective approach to strengthening P&R systems in SEE. Conclusions Further reforms aiming to develop transparent and robust national decision-making frameworks (including oversight) and build institutional HTA-related and decision-making capacity are awaited in most of SEE coun